APLS
Apellis Pharmaceuticals Inc (APLS)
Healthcare • NASDAQ • $41.03+0.05%
- Symbol
- APLS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $41.03
- Daily Change
- +0.05%
- Market Cap
- $5.25B
- Trailing P/E
- 38.36
- Forward P/E
- -168.02
- 52W High
- $41.14
- 52W Low
- $16.10
- Analyst Target
- $40.93
- Dividend Yield
- N/A
- Beta
- -0.25
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the pote…
Company websiteResearch APLS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.